Many Bright Ideas Technologies (TSXV:MBI.H) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Many Bright Ideas Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Many Bright Ideas Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Many Bright Ideas Technologies ROCE % Historical Data

The historical data trend for Many Bright Ideas Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Many Bright Ideas Technologies ROCE % Chart

Many Bright Ideas Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

Many Bright Ideas Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Many Bright Ideas Technologies ROCE % Calculation

Many Bright Ideas Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.078	/	( ( (0.004 - 0.094)	+	(0.003 - 0.173) )	/ 2 )
	=	-0.078	/	( (-0.09	+	-0.17)	/ 2 )
	=	-0.078	/	-0.13
	=	60.00 %

Many Bright Ideas Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-0.06	/	( ( (0.008 - 0.161)	+	(0.003 - 0.173) )	/ 2 )
	=	-0.06	/	( ( -0.153	+	-0.17 )	/ 2 )
	=	-0.06	/	-0.1615
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Many Bright Ideas Technologies (TSXV:MBI.H) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Many Bright Ideas Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Many Bright Ideas Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Many Bright Ideas Technologies (TSXV:MBI.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Many Bright Ideas Technologies Inc (TSXV:MBI.H) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MBGNF:USA

Address

598 East Kent Avenue South, Vancouver, BC, CAN, V5X 4V6

Website

http://www.medbiogene.com

Many Bright Ideas Technologies Inc is a Canada-based life science company. It focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The company is engaged in managing the license and rights to GeneFx Lung, which is a proprietary gene expression-based test for identifying those patients with early-stage non-small-cell lung cancer.

Many Bright Ideas Technologies (TSXV:MBI.H) Headlines

No Headlines